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Abstract
Background: Physiological changes during pregnancy may
affect laboratory parameters. Reference values based on sam-
ples from non-pregnant women are not necessarily useful for
clinical decisions during pregnancy. There is a need to estab-
lish reference values during pregnancy in order to recognize
pathological conditions.
Methods: Eight hundred and one women with expected nor-
mal pregnancies were included in the study. Of these, 391
had no complications during pregnancy, delivery, or the early
postpartum period. Blood samples were obtained at gesta-
tional weeks 13–20, 21–28, 29–34, 35–42, at labor, and 1
and 2 days postpartum. Reference intervals were calculated
for 36 tests as recommended by the International Federation
of Clinical Chemistry and Laboratory Medicine.
Results: Many tests showed such large variations indicating
that gestational age-specific reference intervals were neces-
sary. Other tests had different but stable values when com-
pared to non-pregnant women. A minor decrease in albumin
levels was observed. This was not only due to pregnancy-
associated hemodilution, since other components with the
same or a larger molecular diameter did not show a similar
decrease. Many tests exhibited a broad distribution around
vaginal delivery and in the early postpartum period.
Conclusions: Only a few parameters were unaffected during
uncomplicated pregnancy, delivery, and the early postpartum
period suggesting that implementation of gestational age-
specific reference intervals is necessary.
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Introduction
Physiological changes that occur during pregnancy may
affect biochemical parameters. Most laboratory information
systems (LIS) report reference values based on samples
obtained from non-pregnant women, and these are not nec-
essarily useful for clinical decisions during pregnancy. Some
gestational age-specific reference intervals have been report-
ed. However, the studies often used different analytical meth-
ods and many were based on a mixture of complicated and
uncomplicated pregnancies (1–21). The reported differences
in results are difficult to interpret, and most of these studies
do not fulfill the International Federation of Clinical Chem-
istry and Laboratory Medicine (IFCC) recommendation of a
minimum sample size of 120 individuals for calculation of
reference values (22).
In the present study, we report gestational age-specific ref-
erence intervals for 36 analytical quantities in 391 women
with uncomplicated pregnancies, vaginal deliveries, and the
early postpartum period.
Materials and methods
Study participants and samples
Eight hundred and one healthy Caucasian women )18 years of age
with a singleton pregnancy were recruited from among 2147 women
attending first trimester screening between June 2006 and October
2007. All the women invited to participate in the study had normal
nuchal translucency scans, as well as normal free b-human chori-
onic gonadotropin and pregnancy-associated plasma protein A.
Women with any disease, medicine intake, or previous obstetric
complications were excluded. Gestational age was estimated by
crown rump length, as determined by an ultrasound scan performed
at 11–13 weeks by three Fetal Medicine Foundation certified mid-
wives. The study was approved by the Local Research Ethics Com-
mittee (No. KA 05065), and all women gave informed oral and
written consent. Each woman was scheduled for collection of blood
samples at gestational weeks 13–20, 21–28, 29–34, 35–42, during
active labor, and at postpartum days 1 and 2. Blood pressure, urine
dipstick results, and other clinical data were obtained from special
pregnancy charts and from the medical record. Of the 801 women
recruited, 26 were excluded (non-Caucasian, medicine intake, trans-
ferred to another hospital, miscarriage/still birth, and one death
caused by pulmonary embolism). In addition, 55 women dropped
out of the study and 78 women had pregnancy-related complications
(group B streptococcal infection, verified urinary infection, vaginal
bleeding, preeclampsia, hypertension, pruritus gravidarum, and
intrauterine growth retardation). Sixty-seven women had an elective
cesarean section and 180 had complicated deliveries (preterm deliv-
ery, premature rupture of membranes for more than 24 h, vacuum
extraction, acute cesarean section, bleeding more than 500 mL, third
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and fourth degree perineal laceration, placental retention/intrauterine
palpation, and shoulder dystocia). Four women had postpartum
complications (endomyometritis and urinary infection). Thus, 391
women had a complete uncomplicated pregnancy, vaginal delivery,
and normal postpartum period.
Laboratory methods
Blood samples were drawn into Vacutainer tubes containing triso-
dium ethylenediaminetetraacetic acid (EDTA) for hematological
analysis, and lithium heparin gel tubes for biochemical analysis (BD
Medical Systems, Franklin Lakes, NJ, USA or Greiner Bio-One,
Kremsmuenster, Austria). Samples were transported to the labora-
tory by the phlebotomists and processed according to routine lab-
oratory methods. The samples were registered in the LIS and
analyzed upon arrival with all other samples arriving at the labo-
ratory. Samples with pre-analytical processing times longer than the
stability of the analyte in blood (as indicated in Table 1) were
excluded from the calculations. The analyzed parameters, with
abbreviations, traceability, stability, and method characteristics, are
listed in Table 1. Analysis was performed using the Advia 2120
Hematology System (Siemens Medical Solutions Diagnostics, Tar-
rytown, NY, USA); Immulite 2500 (Siemens Healthcare Diagnos-
tics, Deerfield, IL, USA); Vitros 950 Chemistry System (Johnson
& Johnson, Rochester, NY, USA); and Cobas Integra 400 plus
(Roche, Basel, Switzerland). All tests were performed according to
the manufacturers’ specifications and laboratory standards, accord-
ing to ISO-15189 certification. At the end of the study, all data were
retrieved from the LIS. Laboratory results were not made available
to the clinicians during the study.
Statistical methods
Reference ranges (2.5th and 97.5th percentiles) with 90% confi-
dence interval (CI) were calculated for each test and gestational
period. The non-parametric bootstrap method with 500 iterations
(RefVal version 4.11 software) was used in accordance with IFCC
recommendation (22). Outliers were removed using Dixon’s algo-
rithm. Box-plots were constructed using SPSS 15.2 for Windows
(SPSS Inc., Chicago, IL, USA).
SAS version 9.1. was used for all other calculations (SAS Insti-
tute Inc., Cary, NC, USA). A mixed model with repeated measures
test was performed separately on data during pregnancy and around
delivery after examination of the distribution using histograms and
probability graphs and the Kolmogorov-Smirnov statistic. For sam-
ples -50 observations, the Shapiro Wilks statistic was used to test
for normality. The equality of variances was assessed using the
Levene test. To obtain normal distributions with good approxima-
tion, it was necessary to transform 23 of the 36 quantities. Holm’s
test was used to correct for multiple testing. Statistical significance
was defined as p-0.05.
Results
The women included in the study had a mean age of 32 years
and a body mass index (BMI) of 22 kg/m2. Forty-four per-
cent were nulliparous. The mean gestational age at delivery
was 283 days, and mean birth weight was 3601 g. Two new-
borns had Apgar scores of -7 after 5 min. For comparison,
all women delivering at Gentofte Hospital during the same
period had a mean age of 33 years, a BMI of 23 kg/m2, and
43% were nulliparous.
Reference intervals are shown in Table 2, which also
includes general reference intervals (23, 24). Only a few tests
did not change significantly during pregnancy or around time
of delivery (Table 3). However, many of the changes are
clinically insignificant. Graphical illustrations of the distri-
bution of some tests are indicated by box plots in Figure 1,
with shaded general reference intervals (23, 24). Our sug-
gested reference intervals are listed in Table 4.
Discussion
We report the 2.5th and 97.5th percentiles of gestational
age-specific reference intervals for 36 laboratory blood tests,
calculated in accordance with the recommendations of the
IFCC for statistical treatment of reference values (22). We
used an unprecedented number of women (ns391) without
any complications during pregnancy, delivery, or in the early
postpartum period. Some components of the blood samples
can show minor differences in stability at shorter time
periods than those indicated in Table 1. However, a prag-
matic stability time was selected in order to provide equiv-
alent processing time and storage conditions to those found
in daily practice.
Results from nearly half of the 801 women were omitted
before establishing the reference intervals. This major reduc-
tion of potentially healthy pregnant participants could be a
concern. However, it was important to consider only women
with totally uncomplicated pregnancies in order to be sure
that the results would not be influenced by any pathological
condition. In addition, we compared the mean values and
distribution of results at each gestational period for the 391
women with the values obtained for the women who were
excluded and found only minor sporadic differences between
the two groups (data not shown). Thus, we could have used
data from all 801 women and obtained essentially the same
reference intervals as shown in Table 2. The present study
population was similar to that of the excluded women, and
to all women delivering at our hospital during the same time
period with respect to age, parity, and BMI.
Only a few analytical quantities remained unchanged dur-
ing pregnancy. Some changes were minor and remained
within the non-pregnant reference intervals. Unfortunately,
we had too few samples collected before gestational week
13, and thus we cannot describe changes seen early in preg-
nancy. Some parameters are reported to change very early as
can be suspected from our first time period of weeks 13–20
for albumin (ALB) (Figure 1). Some of our observations
were in agreement with those reported previously (1, 3, 6, 7,
10, 17, 19, 21). At delivery and during the early postpartum
period, essentially all parameters changed, as reported by
other investigators (6, 25). In the following discussion, we
focus on instances in which our results differ from recently
published reference values for pregnant women.
Alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST) did not differ from the non-pregnant reference
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Table 1 Performed tests, abbreviations and analytical details.
Test (abbreviation) CV Method Traceability Stability
Alanine aminotransferase (ALT) 3.0 Vitros 165 5281 IFCC method 96
Albumin (ALB) 1.9 Vitros 819 6057 NIST SRM 927c 144
198 8211
Alkaline aminotransferase (ALP) 3.6 Vitros 105 3180 IFCC method 96
Aspartate aminotransferase (AST) 2.2 Vitros 843 3815 IFCC method 168
Bilirubin (BIL) 4.9 Vitros 838 3051 Jendrassic-Grof – 24
161 2365 Doumas method
Cholesterol (CHOL) 4.6 Integra Calibrator f.a.s. 144
03039773190 (ID-MS)
Cholesterol high-density 3.5 Integra C.f.a.s. Lipids CDC 144
lipoprotein (HDL) 03038637322 (dextran sulfate &
Abell-Kendall)
Cholesterol low-density NA Calculated NA 144
lipoprotein (LDL)
Cholesterol very-low-density NA Calculated NA 144
lipoprotein (VLDL)
C-reactive protein (CRP) 15.6 Integra CRM 470 24
20764930322
Creatinine (CREA) 1.1 Vitros 814 1947 NIST SRM 912a 24
Hematocrit (HCT) 2.6 ADVIA 2120 None 4
Hemoglobin (Hb) 1.4 ADVIA 2120 ICSH – NCCLS H-15A 72
Iron (IRON) 1.6 Vitros 151 5808 NIST SRM 937 24
192 4547
Iron binding capacity NA Calculated None NA
saturation (TIBC)
Lactate dehydrogenase (LDH) 1.5 Vitros 838 4489 Pyruvate/lactate – 8
Buhl method
Leukocyte count (WBC) 2.9 ADVIA 2120 Reference method 48
T03-3685-52
Basophil count (BASO) 73.6a ADVIA 2120 None 72
Eosinophil count (EOS) 14.6 ADVIA 2120 None 24
Lymphocyte count (LYMP) 4.2 ADVIA 2120 None 24
Monocyte count (MONO) 8.8 ADVIA 2120 None 10
Neutrophil count (NEUT) 2.0 ADVIA 2120 None 72
Mean corpuscular 2.1 ADVIA 2120 None 48
hemoglobin (MCH)
Mean corpuscular hemoglobin 2.1 ADVIA 2120 None 144
concentration (MCHC)
Mean erythrocyte 1.3 ADVIA 2120 NCCLS H-7A2 4
corpuscular volume (MCV)
Platelet count (PLT) 4.6 ADVIA 2120 Class A 24
hemocytometer and
phase contrast
microscopy
Potassium (K) 1.4 Vitros 815 7596 NIST SRM 918a 24
Red blood cell count (RBC) 1.7 ADVIA 2120 Reference method 48
T03-3685-52
Sodium (Na) 0.7 Vitros 837 9034 NIST SRM 919a 24
Thyroid stimulating hormone (TSH) 6.7 Immulite L5KRT WHO 2nd IRP 80/558 24
Thyroxine free (FT4) 14.9 Immulite L5KF4 Internal 24
Transferrin (TRAN) 3.7 Integra CRM 470 24
03015050122
Triglyceride (TRIG) 4.8 Integra Calibrator f.a.s. 144
20767107322 (ID-MS)
Triiodothyronine total (T3) 15.6 Immulite L5KT3 Internal 24
Urea nitrogen (BUN) 6.5 Vitros 810 2204 NIST SRM 912a 24
Uric acid (URIC) 1.9 Vitros 194 3927 NIST SRM 913a 24
Total analytical imprecision for the method used to calculate the reference intervals given for each test as an average variation coefficient
(CV%) of three levels of internal controls through 1 year (aonly high level control). Instruments, reagents, and traceability are indicated.
Samples with pre-analytical processing times longer than the stability in blood (in hours) were excluded from the calculations.
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intervals during pregnancy. This is in agreement with other
studies (3, 19). However, some authors have reported vari-
ations during pregnancy, although these variations are within
the non-pregnant reference intervals (1, 7, 10), and some
have reported lower levels than those reported here (1, 7,
16). Though not stated, the older papers undoubtedly used
assays lacking the addition of pyridoxal phosphate, and this
might account for the observed differences. Ethnicity, dietary,
or lifestyle could also play a role. In the present work, we
observed an increase in alkaline phosphatase (ALP) and a
slight increase in lactate dehydrogenase (LDH) (Figure 1),
consistent with other studies (1, 16, 19). At delivery and
during the postpartum period, ALT, AST, ALP, and LDH
activities increased above the upper percentile for non-preg-
nant women. The postpartum increase in ALT and AST
activity has been reported previously, with explanations, such
as tissue trauma, exercise, and changes in blood volume (25).
However, even the women in the present study with uncom-
plicated deliveries showed similar results.
During pregnancy, we found stable C-reactive protein
(CRP) values, but at higher concentrations compared with
non-pregnant women (Figure 1). Several authors have report-
ed stable, but generally higher or rising CRP values during
pregnancy (2, 15, 20). Larsson et al. reported a higher fluc-
tuating level, especially around the time of delivery, and
similar to our results (11), whereas others have shown stable
values (14). The methods used to measure the analyte differ
from study to study, and the early reports were probably not
standardized against the international reference material
(CRM 470) for serum proteins.
We confirmed a stable higher upper reference level for
white blood cells (WBC) during pregnancy (Figure 1), as
described in previous studies (2, 12). We observed that the
WBC peaked at delivery, with a reference interval of
8.2–25.8 =109/L in uncomplicated deliveries, hampering the
use of this parameter as a marker for infection during deliv-
ery. The same observation applies to the use of CRP.
A decrease in platelets was detected at day 1 postpartum,
probably due to consumption during separation and delivery
of the placenta. This is in contrast to Dahlstrøm et al. who
found no change in platelets after vaginal delivery, however,
their study included 11 participants only (4).
Stable, but slightly lower values for hemoglobin (Hb),
hematocrit (HCT), and red blood cell count (RBC) were
observed during pregnancy, in contrast to the results reported
by others (13, 19). The Dutch cohort showed a decrease in
all three components (22), although both Dutch and Danish
women were supplemented with oral iron. The women
included in our study were not iron deficient, judged by fair-
ly stable normal levels of iron, transferrin (TRAN), and iron
binding capacity (TIBC) (Figure 1). Interestingly, the study
of Milman et al. that was conducted in our area more than
10 years ago showed an increase in Hb and HCT, and a fairly
stable RBC in spite of the fact that women were supple-
mented with less iron (20–80 mg/day) compared to what our
women received (50–70 mg/day) (13). One possibility is that
compliance has changed.
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Table 3 Equations predicting the value of quantity (possibly transformed) as a function of gestation week during pregnancy (weeks 13–40)
and as a function of days at delivery (coded as 1), 1st, post-partum day (coded as 2), and 2nd, post-partum day (coded as 3).
Test (Y) Estimated equation: YsinterceptqB=tqC=t=ta
Pregnancy (weeks 13–40) Delivery, day 1 and 2 post-partum
Intercept B C Intercept B C
Ln(ALT) –1.4761 0.01743b 0.00039b –1.4164 0.1004b ns
ALB 48.427 –0.8285b 0.01213b 42.8311 –9.9024b 2.164b
Ln(ALP) 0.2774 –0.04766b 0.001697b 1.649 –0.5324b 0.09583b
1/AST 2.024 0.04921b –0.00096b 3.3521 –1.4403b 0.2965b
Ln(BIL) 2.5688 –0.0979b 0.0001685b 1,2292 0.2578b –0.09496b
CHOL 2.1382 0.2194b –0.00265b 8.4098 –2.1053b 0.4499b
HDL 1.5281 0.05081b –0.00102b 2.3653 –0.327b 0.06065b
Sqrt(LDL) 0.8347 0.05238b –0.00070b 2.1707 –0.4153b 0.09056b
Ln(VLDL) –1.0972 0.03388b ns 0.2515 –0.2111b 0.04641b
Ln(CRP) 3.5275 ns ns 0.6792 4.0387b –0.8067b
Ln(CREA) 4.1971 –0.0152b 0.000324b 4.05 0.07413b –0.01358b
HCT 0.4276 –0.00572b 0.000107b 0.4184 –0.0544b 0.01089b
HGB 150.14 –1.9215b 0.03628b 149.21 –20.6338b 4.1827b
Sqrt(IRON) 5.3321 –0.08043b 0.001338b 3.7688 0.1805b –0.1317b
Ln(TIBC) –0.4367 –0.07433b 0.001011b –2.2319 0.3536b –0.1194b
Ln(LDH) 1.0889 –0.01949b 0.000423b 0.559 0.6772b –0.1427b
Ln(WBC) 1.9103 0.0221b –0.00032b 2.6345 0.09184b –0.05047b
Ln(BASO) –3.7947 0.005754b nsc –3.1479 nsc ns
Ln(EOS) –2.6079 0.04049b –0.00085b –2.1146 –0.7584b 0.3134b
Ln(LYMPH) 0.7397 –0.01439b 0.000327b 0.1092 0.5763b –0.1153b
Ln(MONO) –1.0518 0.01139b ns –0.8327 0.5342b –0.157b
Ln(NEUT) 1.4736 0.0319b –0.00050b 2.4319 0.05416b –0.05018b
MCH 28.9161 0.1824b –0.00307b 31.369 ns ns
MCHC 354.99 ns ns 335.14 –1.101b ns
MCV 79.7973 0.6379b –0.01095b 87.2378 0.5269b ns
Ln(PLT) 5.4513 0.009562b –0.00022b 5.6363 –0.1925b 0.05002b
K 3.9913 –0.02919b 0.000571b 3.7017 ns ns
RBC 5.1573 –0.08801b 0.001617b 4.7772 –0.6589b 0.132b
Na 138.41 ns ns 135.78 1.0283b ns
Sqrt(TSH) 1.1943 0.003584b ns 2.0362 –0.5700 0.14659b
FT4 18.8806 –0.2845b 0.003368b 16.0155 –3.4858b 0.8424b
Ln(TRANS) 3.1524 0.03362b –0.00035b 4.1805 –0.2872b 0.05295b
Ln(TRIG) –0.3044 0.03413b ns 1.0834 –0.2414b 0.05438b
T3 1.5347 0.05069b –0.00082b 3.3307 –1.1812 0.3019b
Ln(BUN) 1.4703 –0.02908b 0.00499b 1.4343 –0.3719b 0.08701b
Ln(URIC) 5.081 –0.00568b 0.000446b 5.6072 0.02609b ns
aB and C are the coefficients of the equation and t is the gestations week (during pregnancy) or days relative to delivery (delivery and
postpartum period). For instance the predicted value of ln(ALP) in gestation week 18 is ln(ALP)s0.2774–0.04766=18q0.001697=
18=18s–0.030652. Then the predicted value of ALPsEXP(–0.030652)s0.9698. bp-0.05. cWhen included in initial model the B or C
coefficient was not significantly (p-0.05) different from 0 and therefore not included in final model.
ALB concentrations in the present study were lower than
the non-pregnant reference interval, with a slight decrease in
mean values of about 9% from gestational weeks 13–20 to
35–42 (Table 2, Figures 1 and 2.). During early pregnancy,
we observed nearly identical values at gestational weeks
13–20 as described by Larsson et al. for gestational weeks
7–17, although they found a more pronounced decrease as
pregnancy progressed (10). The instrument used in the pres-
ent study used a bromcresol green (BCG) method for meas-
uring ALB, whereas Larsson et al. used bromcresol purple
(BGP) (10); both studies used heparin plasma. The two
methods rely on dye binding to ALB, but each dye does so
by a different mechanism. Discrepancies between results
obtained by the two methods have been described (26–28),
probably due to a matrix effect. Fibrinogen increases during
pregnancy by a factor of two (8) and this might account for
the difference in measurement of ALB by the two methods
(29, 30). Immunologically determined ALB concentrations
during pregnancy decreased by nearly 30% between gesta-
tional weeks 6–13 and 37–42 (9). It is unclear which obser-
vation of ALB concentrations during pregnancy is correct
(9–11).
Many authors and textbooks have described a 10%–15%
decrease in ALB during pregnancy (8, 19, 31). Most authors
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Figure 1 Gestational age-specific reference intervals.
Box plots show the range of data from the 25th to the 75th percentile, while the bar in the middle of each box plot represents the median
value. The ends of the ‘‘whiskers’’ represent the highest and lowest values. Circles and asterisks indicate outliers (1.5=the interquartile
range) and extreme values (3.0=the interquartile range) outside the central box. Shaded areas represent non-pregnant normal values.
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Figure 2 Observed and predicted mean albumin levels during pregnancy.
Estimated equation (triangle): albumins48.427q8285=tq01213=t=t, t is the gestations week, observed mean (filled circles). Number
of observations per gestation week are shown as columns.
have explained the decrease in ALB due to ‘‘hemodilution’’,
a phrase that has been used to describe the effect of plasma
volume expansion (1, 9, 11). The increase in plasma volume
during pregnancy cannot be detected before gestation week
6, and increases by 10%–15% at 6–12 weeks of gestation,
expanding rapidly until 30–34 weeks, after which there is
only a modest rise (32, 33). Unfortunately, we have too few
observations in the early period. However, the larger proteins
a2-macroglobulin (9) and high-density lipoprotein (HDL)
(Table 2) show no change during pregnancy. It is unlikely
that the expansion in plasma volume reduces ALB concen-
trations only, and not the concentration of macromolecules
of similar or larger size, unless synthesis or catabolism of
ALB and other plasma macromolecules are also affected by
pregnancy.
The total ALB mass increases during pregnancy (32–34),
with an increased synthesis rate of 50% to ;9 g/day (34).
This production rate should compensate for the increase in
plasma volume of 310 mL seen between 6 and 12 weeks of
gestation (32), since a plasma concentration of 35 g/L cor-
responds to about 10 g in 42 days. We suggest that increased
catabolism of ALB provides essential amino acids to the
fetus and placenta, exceeding the capacity of the liver to
maintain a constant concentration of ALB during pregnancy.
A lower level of plasma ALB during pregnancy may also
represent a well controlled hormonal state that is beneficial
for fetal development.
Potassium was stable throughout pregnancy, although the
reference values for pregnant women were slightly lower
than for non-pregnant women. This is in contrast to Larsson
et al. who observed a minor increase, and a much higher
97.5th percentile during pregnancy with values above
5 mmol/L (10). This difference might be due to different
pre-analytical conditions for the samples in the two studies.
The potassium concentration in plasma may increase due to
cellular leakage during storage before centrifugation. We
eliminated samples that had more than 4 h time elapsed from
collection of blood to separation of plasma. In addition, our
samples were prepared without pre-analytical storage and
freezing, and samples were analyzed immediately after sep-
aration of plasma. Larsson et al. do not provide information
about these pre-analytic details (10).
The method we used to measure potassium is a variant of
the direct ion selective electrode method, whereas Larsson
et al. employed an indirect method (10). As judged by our
external quality control system from Labquality, Helsinki,
Finland, our method measures potassium ;0.15 mmol/L
higher compared with the indirect methods. The indirect
methods are sensitive to changes in plasma protein (35),
resulting in over-estimation of potassium at lower protein
concentrations, as observed during pregnancy. Our results are
in accordance with van Buul et al., who found fairly stable
potassium values using flame photometry, which is unaf-
fected by interfering substances in the plasma (19).
We also observed stable levels of sodium that were very
close to the reference interval for non-pregnant women, and
in accordance with the findings obtained using flame pho-
tometry (19). Larsson et al. described only slightly lower
concentrations of sodium than the present study during early
pregnancy, but at partus they report a nearly 5 mmol/L lower
2.5 percentile than ours (10).
An alternative explanation for the discrepancy between the
results is a difference in dietary intake of sodium and potas-
sium between pregnant Swedes and pregnant Danes and
Dutch. Pregnant women in Sweden are recommended to fol-
low a low-sodium diet (The National Food Administration),
and some even recommend using mineral salts that are rel-
atively low in sodium and high in potassium. In Denmark,
no such recommendations exist. The salt intake hypothesis
assumes that pregnant women are more sensitive to salt
intake than non-pregnant women. Such a difference in sen-
sitivity to salt intake occurs in rats. Pregnant rats exposed to
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a low-sodium diet show a decrease in sodium and an increase
in potassium, whereas non-pregnant rats do not (36). Honda
et al. reported similar results for rats fed standard
fodder (37).
The observations concerning pronounced differences in
plasma concentration of ALB and electrolytes between the
present study and the study performed by Larsson et al. (10)
stress the importance of establishing local reference values,
since lifestyle habits, including dietary habits, may be reflect-
ed in the composition of plasma. Analytical methods may
also influence results.
Determination of local reference intervals, as performed
in the present study, is both cumbersome and expensive. For
frequently performed tests, establishing reference intervals
retrospectively from archived data is feasible, as shown in
the Realab project (38). In our case, identification of the
presence of pregnancy and the gestational age required some
effort. We found virtually identical reference intervals to
those obtained in the present study when the method was
evaluated on a few tests with 5 years of data from a single
ward where only women in late pregnancy are treated.
As most LIS report reference intervals based on age and
gender only, we have designed a simple method to report the
correct gestational age-specific reference values. A test is
given a period suffix and defined as a separate test with the
correct reference values. The test with its suffix appears on
the ordering screen or sheet as a new test, although the anal-
ysis is performed exactly the same as usual. In this way,
‘‘albumin’’ may also appear as ‘‘albumin gestation weeks
13–20’’, etc. This procedure eliminates the need for pocket
folders with reference values for pregnant women.
Acknowledgements
We thank the participating women for their conscientious coopera-
tion and the entire staff at the Departments of Obstetrics and Clin-
ical Biochemistry for their expert assistance. A special thanks to
Dr. Per Winkel for statistical assistance.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that
there are no conflicts of interest regarding the publication of this
article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Bacq Y, Zarka O, Bre´chot JF, Mariotte N, Vol S, Tichet JT, et
al. Liver function tests in normal pregnancy: a prospective study
of 103 pregnant women and 103 matched controls. Hepatology
1996;23:1030–4.
2. Belo L, Santos-Silva A, Rocha S, Caslake M, Cooney J, Pereira-
Leite L, et al. Fluctuations in C-reactive protein concentration
and neutrophil activation during normal pregnancy. Eur J Obs-
tet Gynecol Reprod Biol 2005;123:46–51.
3. Carter J. Liver function in normal pregnancy. Aust NZ J Obstet
Gynaecol 1990;30:296–302.
4. Dahlstrøm BL, Nesheim BI. Post partum platelet count in
maternal blood. Acta Obstet Gynecol Scand 1994;73:695–7.
5. Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, Leve-
no KJ, et al. Thyroid-stimulating hormone in singleton and twin
pregnancy: importance of gestational age-specific reference
ranges. Obstet Gynecol 2005;106:753–7.
6. Edelstam G, Lo¨wbeer C, Kral G, Gustafsson SA, Venge P. New
reference values for routine blood samples and human neutro-
philic lipocalin during third trimester pregnancy. Scand J Clin
Lab Invest 2001;61:583–92.
7. Girling JC, Dow E, Smith JH. Liver function tests in pre-
eclampsia: importance of comparison with a reference range
derived for normal pregnancy. Br J Obstet Gynaecol 1997;
104:246–50.
8. Gronowski AM, editor. Handbook of clinical laboratory testing
during pregnancy. Totowa, NJ, USA: Humana Press, 2004.
9. Kristensen K, Lindstro¨m V, Schmidt C, Blirup-Jensen S, Grubb
A, Wide-Swensson D, et al. Temporal changes of the plasma
levels of cystatin C, beta-trace protein, beta2-microglobulin,
urate and creatinine during pregnancy indicate continuous alter-
ations in the renal filtration process. Scand J Clin Lab Invest
2007;67:612–8.
10. Larsson A, Palm M, Hansson LO, Axelsson O. Reference val-
ues for clinical chemistry tests during normal pregnancy. Br J
Obstet Gynaecol 2008;115:874–8.
11. Larsson A, Palm M, Hansson LO, Basu S, Axelsson O. Ref-
erence values for a1-acid glycoprotein, a1-antitrypsin, albu-
min, haptoglobin, C-reactive protein, IgA, IgG and IgM during
pregnancy. Acta Obstet Gynecol Scand 2008;87:1084–8.
12. Lurie S, Rahamim E, Piper I, Golan A, Sadan O. Total and
differential leukocyte counts percentiles in normal pregnancy.
Eur J Obstet Gynecol Reprod Biol 2008;136:16–9.
13. Milman N, Bergholt T, Byg KE, Eriksen L, Hvas AM. Refer-
ence intervals for haematological variables during normal preg-
nancy and postpartum in 434 healthy Danish women. Eur J
Haematol 2007;79:39–46.
14. Nielsen FR, Bek KM, Rasmussen PE, Qvist I, Tobiassen M.
C-reactive protein during normal pregnancy. Eur J Obstet
Gynecol Reprod Biol 1990;35:23–7.
15. Romem Y, Artal R. C-reactive protein in pregnancy and in the
postpartum period. Am J Obstet Gynecol 1985;151:380–3.
16. Ruiz-Extremera A, Lo´pez-Garrido MA, Barranco E, Quintero
MD, Ocete-Hita E, Mun˜oz de Rueda P, et al. Activity of hepatic
enzymes from week sixteen of pregnancy. Am J Obstet Gyne-
col 2005;193:2010–6.
17. Sill PR, Lind T, Walker W. Platelet values during normal preg-
nancy. Br J Obstet Gynaecol 1985;92:480–3.
18. Stricker T, Echenard M, Chevaller M-C, Perez V, Quinn FA,
Stricker R. Evaluation of maternal thyroid function during
pregnancy: the importance of using gestational-age specific ref-
erence intervals. Eur J Endocrin 2007;157:509–14.
19. van Buul EJ, Steegers EA, Jongsma HW, Eskes TK, Thomas
CM, Hein PR. Haematological and biochemical profile of
uncomplicated pregnancy in nulliparous women; a longitudinal
study. Neth J Med 1995;46:73–85.
20. Watts DH, Krohn MA, Wener MH, Eschenbach DA. C-reactive
protein in normal pregnancy. Obstet Gynecol 1991;77:176–
80.
248 Klajnbard et al.: Gestational age-specific reference intervals
Article in press - uncorrected proof
21. Wichman K, Ryde´n G. Blood pressure and renal function dur-
ing normal pregnancy. Acta Obstet Gynecol Scand 1986;
65:561–6.
22. Solberg HE. The IFCC recommendation on estimation of ref-
erence intervals. The RefVal program. Clin Chem Lab Med
2004;42:710–4.
23. Felding P, Rustad P, Ma˚rtensson A, Kairisto V, Franzson L,
Hyltoft Petersen P, et al. Reference individuals, blood collec-
tion, treatment of samples and descriptive data from the ques-
tionnaire in the Nordic Reference Interval Project 2000. Scand
J Clin Lab Invest 2004;64:327–42.
24. Nordin G, Ma˚rtensson A, Swolin B, Sandberg S, Christensen
NJ, Thorsteinsson V, et al. A multicentre study of reference
intervals for haemoglobin, basic blood cell counts and eryth-
rocyte indices in the adult population of the Nordic countries.
Scand J Clin Lab Invest 2004;64:385–98.
25. David AL, Kotecha M, Girling JC. Factors influencing post-
natal liver function tests. Br J Obstet Gynaecol 2000;107:1421–6.
26. Clase CM, St Pierre MW, Churchill DN. Conversion between
bromcresol green- and bromcresol purple-measured albumin in
renal disease. Nephrol Dial Transpl 2001;16:1925–9.
27. Duly EB, Grimason S, Grimason P, Barnes G, Trinick TR.
Measurement of serum albumin by capillary zone electropho-
resis, bromocresol green, bromocresol purple, and immunoas-
say methods. J Clin Pathol 2003;56:780–1.
28. Meng QH, Krahn J. Lithium heparinised blood-collection tubes
give falsely low albumin results with an automated bromcresol
green method in haemodialysis patients. Clin Chem Lab Med
2008;46:396–400.
29. Joseph R, Tria L, Mossey RT, Bellucci AG, Mailloux LU, Ver-
nace MA, et al. Comparison of methods for measuring albumin
in peritoneal dialysis and hemodialysis patients. Am J Kidney
Dis 1996;27:566–72.
30. Hallbach J, Hoffmann GE, Guder WG. Overestimation of albu-
min in heparinized plasma. Clin Chem 1991;37:566–8.
31. Murphy MM, Scott JM, McPartlin JM, Fernandez-Ballart JD.
The pregnancy related decrease in fasting plasma homocysteine
is not explained by folic acid supplementation, hemodilution,
or a decrease in albumin in a longitudinal study. Am J Clin
Nutr 2002;76:614–9.
32. Bernstein IM, Ziegler W, Badger GJ. Plasma volume expansion
in early pregnancy. Obstet Gynecol 2001;97:669–72.
33. Whittaker PG, Lind T. The intravascular mass of albumin dur-
ing human pregnancy: a serial study in normal and diabetic
women. Br J Obstet Gynaecol 1993;100:587–92.
34. Olufemi OS, Whittaker PG, Halliday D, Lind T. Albumin
metabolism in fasted subjects during late pregnancy. Clin Sci
(Lond) 1991;81:161–8.
35. Dimeski G, Barnett RJ. Effects of total plasma protein concen-
tration on plasma sodium, potassium and chloride measure-
ments by an indirect ion selective electrode measuring system.
Crit Care Resusc 2005;7:12–5.
36. Kirksey A, Pike RL, Callahan JA. Some effects of high and
low sodium intakes during pregnancy in the rat. J Nutr 1962;
77:43–51.
37. Honda T, Honda K, Kokubun C, Nishimura T, Hasegawa M,
Nishida A, et al. Time-course changes of hematology and clin-
ical chemistry values in pregnant rats. J Toxicol Sci 2008;
33:375–80.
38. Grossi E, Colombo R, Cavuto S, Franzini C. The REALAB
project: a new method for the formulation of reference intervals
based on current data. Clin Chem 2005;51:1232–40.
